<p>Strata Skin Sciences (SSKN) 发布了其第三季度财报。以下是 Strata Skin Sciences 向投资者提供的信息摘要。</p>
<h3>认识您的 ETF 人工智能分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
<p>STRATA Skin Sciences, Inc. 是一家医疗科技公司，专注于开发和营销创新产品，以治疗皮肤病，重点提供针对银屑病、白癜风和痤疮等疾病的门诊解决方案。</p>
<p>在其 2025 年第三季度财报中，STRATA Skin Sciences 强调了在扩展皮肤病治疗报销代码方面取得的重大进展，在墨西哥获得了 TheraClearX 设备的监管批准，并对其 XTRAC 激光治疗进行了新的临床验证。尽管取得了这些进展，公司报告称由于国际市场挑战，总收入有所下降。</p>
<p>本季度的关键财务指标包括与去年同期的负数相比，轻微的正 EBITDA，设备平均开票额增长 8.5%，毛利率为 60%。然而，总收入同比下降 21%，主要是由于设备收入下降 60%，而全球经常性收入则小幅增长 3%。公司还报告了 160 万美元的净亏损，较去年同期的 210 万美元亏损有所改善。</p>
<p>公司对未来的增长持乐观态度，预计新批准的报销代码和积极的诉讼结果将吸引新客户并增加收入。STRATA 继续专注于成本管理，并通过直接面向消费者的努力和对临床合作伙伴的支持，战略性地扩大其患者基础。</p>
<p>展望未来，STRATA Skin Sciences 将继续致力于完善其商业模式和扩大市场影响力，重点利用新的报销机会，并加强与临床医生的合作关系，以推动未来的增长。</p>

SSKN

<p>STRATA Skin Sciences 发布了其 2025 年第三季度财务业绩，强调了在报销代码、墨西哥的监管批准和临床验证方面的进展。尽管取得了这些进展，总收入下降了 21%，设备收入减少了 60%。公司报告净亏损为 160 万美元，较去年 210 万美元的亏损有所改善。STRATA 对未来的增长持乐观态度，专注于成本管理、市场扩展和利用新的报销机会</p>

<p>Strata Skin Sciences ( (SSKN) ) has released its Q3 earnings. Here is a breakdown of the information Strata Skin Sciences presented to its investors.</p>
<div class="lb-trans"><p>Strata Skin Sciences (SSKN) 发布了其第三季度财报。以下是 Strata Skin Sciences 向投资者提供的信息摘要。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF 人工智能分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
</div><p>STRATA Skin Sciences, Inc. is a medical technology company that specializes in developing and marketing innovative products for the treatment of dermatologic conditions, focusing on in-office solutions for conditions such as psoriasis, vitiligo, and acne.</p>
<div class="lb-trans"><p>STRATA Skin Sciences, Inc. 是一家医疗科技公司，专注于开发和营销创新产品，以治疗皮肤病，重点提供针对银屑病、白癜风和痤疮等疾病的门诊解决方案。</p>
</div><p>In its third-quarter 2025 earnings report, STRATA Skin Sciences highlighted significant progress in expanding reimbursement codes for skin disease treatments, regulatory clearance in Mexico for its TheraClearX device, and new clinical validations for its XTRAC laser treatments. Despite these advancements, the company reported a decline in total revenue due to international market challenges.</p>
<div class="lb-trans"><p>在其 2025 年第三季度财报中，STRATA Skin Sciences 强调了在扩展皮肤病治疗报销代码方面取得的重大进展，在墨西哥获得了 TheraClearX 设备的监管批准，并对其 XTRAC 激光治疗进行了新的临床验证。尽管取得了这些进展，公司报告称由于国际市场挑战，总收入有所下降。</p>
</div><p>Key financial metrics for the quarter included a slight positive EBITDA compared to a negative figure in the previous year, an 8.5% increase in average gross billings per device, and a gross margin of 60%. However, total revenue decreased by 21% year-over-year, primarily due to a 60% drop in equipment revenue, while global recurring revenue saw a modest 3% increase. The company also reported a net loss of $1.6 million, an improvement from the $2.1 million loss in the same period last year.</p>
<div class="lb-trans"><p>本季度的关键财务指标包括与去年同期的负数相比，轻微的正 EBITDA，设备平均开票额增长 8.5%，毛利率为 60%。然而，总收入同比下降 21%，主要是由于设备收入下降 60%，而全球经常性收入则小幅增长 3%。公司还报告了 160 万美元的净亏损，较去年同期的 210 万美元亏损有所改善。</p>
</div><p>The company is optimistic about future growth, driven by the newly approved reimbursement codes and positive litigation outcomes, which are expected to attract new customers and increase revenue. STRATA continues to focus on cost management and strategic expansion of its patient base through direct-to-consumer efforts and support for its clinical partners.</p>
<div class="lb-trans"><p>公司对未来的增长持乐观态度，预计新批准的报销代码和积极的诉讼结果将吸引新客户并增加收入。STRATA 继续专注于成本管理，并通过直接面向消费者的努力和对临床合作伙伴的支持，战略性地扩大其患者基础。</p>
</div><p>Looking ahead, STRATA Skin Sciences remains committed to refining its business model and expanding its market presence, with a focus on leveraging new reimbursement opportunities and strengthening its partnerships with clinicians to drive future growth.</p>
<div class="lb-trans"><p>展望未来，STRATA Skin Sciences 将继续致力于完善其商业模式和扩大市场影响力，重点利用新的报销机会，并加强与临床医生的合作关系，以推动未来的增长。</p>
</div>

STRATA Skin Sciences 公布 2025 年第三季度财务结果